Anthracycline Metabolism and Toxicity in Human Myocardium: Comparisons between Doxorubicin, Epirubicin, and a Novel Disaccharide Analogue with a Reduced Level of Formation and [4Fe-4S] Reactivity of Its Secondary Alcohol Metabolite-Reference-Cited by-同舟云学术

Anthracycline Metabolism and Toxicity in Human Myocardium: Comparisons between Doxorubicin, Epirubicin, and a Novel Disaccharide Analogue with a Reduced Level of Formation and [4Fe-4S] Reactivity of Its Secondary Alcohol Metabolite

Published:2000-11-30 Issue:12 Volume:13 Page:1336-1341
ISSN:0893-228X
Container-title:Chemical Research in Toxicology
language:en
Short-container-title:Chem. Res. Toxicol.

Author:

Minotti Giorgio¹,Licata Sabrina¹,Saponiero Antonella¹,Menna Pierantonio¹,Calafiore Antonio M.¹,Di Giammarco Gabriele¹,Liberi Giovanni¹,Animati Fabio¹,Cipollone Amalia¹,Manzini Stefano¹,Maggi Carlo A.¹

Affiliation:

1. Department of Drug Sciences, G. D'Annunzio University School of Pharmacy, and Department of Cardiac Surgery, G. D'Annunzio University School of Medicine, Chieti; Institute of Pharmacology, Catholic University School of Medicine, Rome; and Menarini Ricerche S. p. A., Pomezia (Rome), Italy

Publisher

American Chemical Society (ACS)

Subject

Toxicology,General Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/tx000143z

Reference23 articles.

1. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses

2. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity.

3. The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein‐1 in cytosolic fractions from human myocardium

4. Role of iron in anthracycline cardiotoxicity: new tunes for an old song?

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In Silico and In Vitro Assessment of Carbonyl Reductase 1 Inhibition Using ASP9521—A Potent Aldo-Keto Reductase 1C3 Inhibitor with the Potential to Support Anticancer Therapy Using Anthracycline Antibiotics;Molecules;2023-04-27

2. Development of a Dose-Adjusted Polygenic Risk Model for Anthracycline-Induced Cardiotoxicity;Therapeutic Drug Monitoring;2023-01-12

3. Pharmacogenetic testing to guide therapeutic decision‐making and improve outcomes for children undergoing anthracycline‐based chemotherapy;Basic & Clinical Pharmacology & Toxicology;2021-05-11

4. Ca2+ Signaling as the Untact Mode during Signaling in Metastatic Breast Cancer;Cancers;2021-03-23

5. Genotype Analysis of ABCC1, NCF4 and CBR3 Polymorphism and the Association With Childhood Acute Lymphoblastic Leukemia in Mexican Childhood Population;Frontiers in Pharmacology;2021-02-02